source
- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and th…Endpoints · 7d ago↗ source
- Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drugTo analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.BioPharma Dive · 8d ago↗ source
- Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseaseArrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer R…